Section Review: Biologicals & Immunologicals: Immunotherapy with interleukin-2: Recent developments

References

• BOSSE M, AUDETCE M, FERLAND C, PELLETIER G, CHUHW, DAKHAMA A, LAVIGNE S, BOULET L-P, LAVIOLEnt M: Gene expression of interleukin-2 in purified human peripheral blood lymphocytes. Immunology (1996) 87:149–154.
   PubMed Web of Science ®Google Scholar
• MORGAN DA, RUSCETTI FW, GALLO R: Selective in vitrogrowth of T-lymphocytes from normal human bone marrows. Science (1976) 193:1007–1010.
   PubMed Web of Science ®Google Scholar
• GILLIS S, FERM MM, OU W, SMITH KA: T-cell growthfactor: parameters of production and a quantitative microassay for activity. J. lmmunol. (1978) 120:2027–2033.
   PubMed Web of Science ®Google Scholar
• GORELIK E, WILTROUT RH, OKUMLTRA K, HABU S, HER-BERMAN RB: Role of NK cells in the control of metastatic spread and growth of tumour cells in mice. Int.J. Cancer (1982) 30:107–112.
   PubMed Web of Science ®Google Scholar
• ORTALDO JR, MASON TA, GERARD JP, HENDERSON LE, FARRAR W, HOPKINS RF, HERBERMAN RB, RABIN H: Effects of natural and recombinant IL-2 on regulation of gamma LPN production and natural killer cell activity: lack of involvement of the TAC antigen for these im-munoregulatory effects. J. Immunol. (1984) 133:779–783.
   PubMed Web of Science ®Google Scholar
• GRIMM EA, TOBB RJ, ROTH JA, NECKARS LM, LACHMAN LB, WILSON DJ, ROSENBERG SA: Lymphokine-activated killer cell phenomenon III. Evidence that IL-2 is suffi-dent for direct activation of peripheral blood lympho-cytes into lymphokine-activated killer cefls.j Exp. Med. (1983) 158:1356–1361.
   Google Scholar
• WATSON J, MOCHUZUKI D: Interleukin-2: a class of T-cell growth factors. Immunol. Rev. (1980) 51:257–278.
   PubMedGoogle Scholar
• ROSENBERG SA: What's new in general surgery? The development of new immunotherapies for the treat-ment of cancer using interleukin-2. Ann. Surg. (1988) 208:121–135.
   PubMed Web of Science ®Google Scholar
• ZUBLER RH, LOWENTHAL JW, ERARD F, HASHIMOTO N, DEVOS R, MACDONALD HR: Activated B-cells express receptors for, and proliferate in response to, pure interleukin-2. J. Exp. Med. (1984) 160:1170–1183.
   PubMed Web of Science ®Google Scholar
• KURT-JONES EA, HAMBERG S, OHARA J, PAUL WE, ABBAS AK: Heterogeneity of helper/inducer T-Iymphocytes. Exp. Med. (1987) 166:1774–1789.
   PubMed Web of Science ®Google Scholar
• TANIGUCHI T, MATSUI H, FUJITA T, TAKAOKA C, ICASHIMA N, YOSHIMOTO R, HAMURO J: Structure and expression of a cloned cDNA for human interleukin-2. Nature (1983) 302:305–310.
   PubMed Web of Science ®Google Scholar
• DEVOS R, PLAETINCK G, CHEROUTRE H, SIMONS G, DEGRAVE W, TAVERNIER J, REMAUT E, HERS W: Molecu-lar cloning of interleukin-2 cDNA and its expression in E. coll. Nucleic Acid Res. (1983) 11:4307–4323.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, GRIMM EA, MCGORAN M, DOYLE M, KAWASAKI E, KOTHS K, MARK DF: Biological activity of recombinant human interleukin-2 produced in Es-chericbia coil. Science (1984) 223:1412–1414.
   PubMed Web of Science ®Google Scholar
• LAFRENIERE RL, ROSENBERG SA: Adoptive immune ther-apy of murine hepatic metastases and recombinant-IL-2 can mediate the regression of both immunogenic and non-immunogenic sarcomas and an adenocarcinoma. Immunol. (1985) 135:4273–4280.
   Web of Science ®Google Scholar
• MULE JJ, SHU S, ROSENBERG SA: The anti-tumour efficacy of lymphokine-activated killer cells and recombinant interleuldn-2 in vivo. J. Immunol. (1985) 135:646–652.
   PubMed Web of Science ®Google Scholar
• IAFRENIERE RL, ROSENBERG SA: Successful immuno-therapy of murine experimental metastases with lym-phokine- activated killer cells and recombinant interleukin-2. Cancer Res. (1985) 45:3735–3741.
   PubMed Web of Science ®Google Scholar
• MULE JJ, SHU SL, SCHWARZ SL, ROSENBERG SA: Adoptiveitnatunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (1984) 225:1487–1489.
   PubMed Web of Science ®Google Scholar
• MULE JJ, ETTINGHAUSEN SE, SPEISS PJ, SHU S, ROSEN-BERG SA: Anti-tumour efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: sur-vival benefit and mechanisms of tumour escape in mice undergoing immunotherapy. Cancer Res. (1986) 46:676–683.
   PubMed Web of Science ®Google Scholar
• PAPA MZ, MULE JJ, ROSENBERG SA: Anti-tumor efficacyof lymphokine-activated killer cells and recombinant interleukin-2 in vivo: successful immunotherapy of established pubnonary metastases from weakly immu-nogenic and nonimmunogenic murine tumors of three distinct histological types. Cancer Res. (1986) 46:4973–4978.
   PubMed Web of Science ®Google Scholar
• MULE JJ, YANG J, SHU S, ROSENBERG SA: The anti-tumorefficacy of lymphokine-activated killer cells and recom-binant interleukin-2 in vivo: direct correlation between reduction of established metastases and eytolytic activ-ity of lymphokine-activated killer cells. J. Immunol. (1986) 136:3899–3909.
   PubMed Web of Science ®Google Scholar
• ETTINGHAUSEN SE, ROSENBERG SA: Immunotherapy ofmurine sarcomas using lymphokine-activated killer cells: optimisation of the schedule and route of admini-stration of recombinant interleukin-2. CancerRes. (1986) 46:2784–2792.
   Web of Science ®Google Scholar
• DEKERNION JB, RAMMING ICP, SMITH RB: The naturalhistory of advanced renal cell carcinoma: a computer analysis. J. Urol. (1978) 120:148–152.
   PubMed Web of Science ®Google Scholar
• FIGLIN RA, PIERCE WC, BELLDEGRUN A: Combination biologic therapy with interleukin-2 and interferon-al-pha in the outpatient treatment of metastatic renal cell carcinoma. Semin. Oncol. (1993) 20:11–15.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, YANG JC, AEBERSOLD PM,LINEHAN WM, SEIPP CA, WHITE DE: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. (1989) 210:474–485.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, YANG JC, TOPALIAN SL, CHANG AE, SCHWARTZENTRUBER DJ, AEBERSOLD P, LEITMAN S, LINEHAN WM, SEIPP CA, WHITE DE, STEIN-BERG SM: Prospective randomised trial of high-dose interleukin-2 alone or in conjunction with lymphok-ine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. (1993) 85:622–632.
   PubMed Web of Science ®Google Scholar
• ABRAMS JS, RAYNOR AA, WIENIK PH, PARKINSON DR,EISENBERGER M, ARONSON FR, GUCALP R, ATKINS MB, HAWKINS MJ: High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma. J. Natl. Cancer Inst. (1990) 82:1202–1206.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, TOPALIAN SL, SCHWARTZEN-TAUBER DJ, WEBER JS, PARKINSON DR, SEIPP CA, EIN-HORN JH, WHITE DE: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA (1994) 271:907–913.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, MUUL LM, CHANG AE, AVIS FP, LEITMAN 5, LINEHAN WM, ROBERTSON CN, LEE RE, RUBIN JT, SEIPP CA, SIMPSON CG, WHITE DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and in-terleukin-2 or high-dose interleukin-2 alone. New Engl. J. Med. (1987) 316:889–897.
   PubMed Web of Science ®Google Scholar
• VON DER MAASE H, GEERTSEN P, THATCHER N, JASMIN C, MERCATELLO A, FOSSA SD, SYMANN M, STOTER G, NAGEL G, ISRAEL L, OSKAM R, PALMER P, FRANKS CR: Recombinant interleukin-2 in metastatic renal cell car-cinoma - a European multicentre Phase II study. Eur. J. Cancer (1991) 27:1583–1589.
   PubMed Web of Science ®Google Scholar
• ROBERTSON CN, LINEHAN WM, PASS HI, GOMELLA LG,HAAS GP, BERMAN A, MERINO M, ROSENBERG SA: Prepa-rative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive Immuno- therapy with interleukin-2 or interleukin-2 plus lym-phokine-activated killer cells. J. Urol. (1990) 144:614–618.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO, OLDHAM RK, TAUER KW, ORE DW, BARTHNM, BLUMENSCHEIN G, ARNOLD J, BIRCH R, WEST WH: Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J. Clin. Oncol. (1991) 9:1233–1240.
   PubMed Web of Science ®Google Scholar
• KORETZ MJ, LAWSON DH, YORK RM, GRAHAM SD, MUR-RAY DR, GILLESPIE TM, LEVITT D, SELL KM: Randomised study of interleukin-2 (IL-2) Alone vs. IL-2 phis lym-phokine-activated killer cells for treatment of mela-noma and renal cell cancer. Arch. Surg. (1991) 126:898–903.
   Google Scholar
• PHILIP T, NEGRIER S, MERCATELLO A, TOGNET E, PALMER P, THIESSE P, FRANKS C: Interleukin-2 in the treatment of metastatic renal cell cancer: 77 patients treated in Lyon. Insights into Immunotherapy (1990) 1:23–30.
   Google Scholar
• NEGRIER S, MERCATELLO A, BRET M, THIESSE P, BLAY JY, CORONEL B, MERROUCHE Y, OSKAM R, FRANKS CR, CLAVEL M, MOSKOVTCHENKO JF, PHILIP T: Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma. Br. J. Cancer (1992) 65:723–726.
   PubMed Web of Science ®Google Scholar
• THOMAS H, BARTON C, SAINT A, DALGLEISH A, WAXMANJ: Sequential interleukin-2 and alpha interferon for renal cell carcinoma and melanoma. Eur.J.Cancer(1992) 28A:1047–1049.
   PubMed Web of Science ®Google Scholar
• GORE ME, GALLIGIONI E, KEEN CW, SORIO R, LORIAUXEM, GROBBEN HC, FRANKS CR: The treatment of metas-tatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2. Eur. J. Cancer (1994) 30A:329–333.
   PubMed Web of Science ®Google Scholar
• ATZPODIEN J, KIRCHNER H, FRANKS CR, KORFER A, PALMER PA, EVERS P, POLIWODA H: Outpatient treat-ment of advanced human cancer using a combination of recombinant interleukin-2 and interferon-a2b. In-sights into Immunotherapy (1990) 1:47–49.
   Google Scholar
• ATZPODIEN J, KIRCHNER H, HANNINEN EL, KORFER A,FENNER M, MENZEL T, DECKERT M, FRANZKE A, JONAS U, POLIWODA H: European studies of interleukin-2 in metastatic renal cell carcinoma. Semin. Oncol. (1993) 20:22–26.
   PubMed Web of Science ®Google Scholar
• BUTER J, SLEIJFER DT, VAN DER GRAFF TA, DE VRIES EGE,WILLEMSE PHB, MULDER NH: A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant inter-leukin-2. Semin. Oncol. (1993) 20: 16–21.
   PubMed Web of Science ®Google Scholar
• ATZPODIEN J, HANNINEN EL, KIRCHNER H, BODENSTEINH, PFREUNSCHUH M, REBMANN U, METZNER B, ILLIGER H-J, JAKSE G, NIESEL T, SCHOLZ H-J, WILHELM S, PIEL-MEIER T, ZAKRZEWSKI G, BLUM G, BEIER J, MULLER G-W, DLTENSING S, ANTON P, ALLHOFF E, JONAS U, POLIWODA H: Multi-institutional home-therapy trial of recombi-nant human interleultin-2 and interferon alpha-2 in progressive metastatic renal cell carcinoma. J. Clin. Oncol. (1995) 13:497–501.
   PubMed Web of Science ®Google Scholar
• HANNINEN EL, KIRCHNER H, ATZPODIEN J: Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J. Urol. In press.
   Google Scholar
• PALMER PA, VINKE J, EVERS P, POURREAU C, OSKAM R, ROEST G, 'VLEMS F, BECKER L, LORIAUX E, FRANKS CR: Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells •• for the treatment of advanced renal cell carcinoma. Eur. J. Cancer (1992) 28A:1038–1044.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, YANG JC, TOPALIAN SL, CHANG AE, SCHWARTZENTRUBER DJ, AEBERSOLD P, LEITMAN 5, LINEHAN WM, SEIPP CA, WHITE DE, STEIN-BERG SM: Prospective randomised trial of high-dose interleukin-2 alone or in conjunction with lymphok-ine-activated killer cells in the treatment of patients with advanced cancer. J. Natl. Cancer Inst. (1993) 85 :622-632. Randomised trial evaluating the value of LAK cells with rIL-2 therapy.
   Google Scholar
• ROSENBERG SA, SCHWARTZ S, SPEISS PJ: Combinationimmunotherapy for cancer: synergistic antitumor in-teractions of interleukin-2, alpha-interferon, and tu-mor-infiltrating lymphocytes. J. Natl. Cancer Inst. (1988) 80:1393–1397.
   PubMed Web of Science ®Google Scholar
• ATZPODIEN J, KORFER A, EVERS P, FRANKS CR, KNIIVER- HOPE J, LOPEZ-HANNINEN E, FISCHER M, MOHR H, DALL-MAN I, HADAM M: Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a Phase II outpatient study. Mol. Biother. (1990) 2:18-26. Subcutaneous administration of rIL-2 to out-patients with minimal toxicity.
   Google Scholar
• VLASVELD LT, RANKIN EM, HEKMAN A, RODENHUIS S,BEIJNEN JH, HILTON AM, DUBBELMAN AC, VYTH-DREESE FA, MELIEF CJM : A Phase I study of prolonged continuous Infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part E clinical aspects. Br. J. Cancer (1992) 65:744–750.
   Web of Science ®Google Scholar
• LISSONI P, BARNI S, ARDIZZOIA A, CRISPINO S, PAOLO-ROSSI F, ARCHILI C, VAGHI M, TANCIN G: Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to Interferon-alpha. Eur. J. Cancer (1992) 28:92–96.
   PubMed Web of Science ®Google Scholar
• WALPOLE ET, DUTCHER JP, SPARANO J, GUCALP R, EINZIGA, PAIETTA E, CIOBANU N, GRIMA K, CALIENDO G, CAVASOTTO G, WIERNIK PH: Survival after Phase 11 treatment of advanced renal cell cardnoma with Taxol or high dose interleukht-2. J. Immunother. (1993) 133:275–281.
   Google Scholar
• JONES M, PHILIP T, PALMER P, VON DER MAASE H, VINKE J, ELSON P, FRANKS CR, SELBY P: The impact of inter-leukin-2 on survival hi renal cancer: a multivariate analysis. Cancer Biother. (1993) 8:275-288. Identification of which patients gain a survival advantage from rIL-2 therapy.
   Google Scholar
• PALMER PA, VINKE J, PHILIP T, NEGRIER S, ATZPODIEN J,KIRCHNER H, OSKAM R, FRANKS CR: Prognostic factors for survival in patients with advanced renal cell carci-noma treated with recombinant inrerleukin-2. Ann. Oncol. (1992) 3:475–480.
   PubMed Web of Science ®Google Scholar
• EREMIN 0: Cancer and the immune response. In: TheImmunological Basis of Surgical Science and Practice. Ere-min 0, Sewell HF (Eds.), Oxford University Press (1992):87–102.
   Google Scholar
• MOORE GE, KLEIN E: Immunotherapy of skin cancer. In: Cancer of the Skin. Andrade R, Gumport SL, Popkin GL, Rees TD (Eds.), WB Saunders, Philadelphia (1976):1647–1661.
   Google Scholar
• PENN I: Principles of tumor immunity: immunocompe-tence and cancer. In: Biologic Therapy of Cancer. DeVita VT, Hellman S, Rosenberg SA (Eds.), JB Lippincott Co., Philadelphia (1991)53–66.
   Google Scholar
• LEGHA S: Current therapy for malignant melanoma.Semin. Oncol. (1989) 16:33–44.
   PubMedGoogle Scholar
• THATCHER N, DAZZI H, GOSH A, JOHNSON RJ: Recombi-nant IL-2 given intrasplenically and intravenously in advanced malignant melanoma: a Phase 1/II study. Cancer Treat. Rev. (1989) 16\(Suppl. 1):49–52.
   Google Scholar
• WEST WH, TAUER KW, YANNELLI JR, MARSHALL GD, ORR DW, THURMAN GB, OLDHAM RK: Constant-infusion re- combinant interleukin- in adoptive immunotherapy of advanced cancer. New Engl. J. Med. (1987) 316:898-905. Initial reports of constant infusion rIL-2 therapy.
   Google Scholar
• DEMCHAK PA, MIER JW, ROBERT NJ, O'BRIEN K, GOULD JA, ATKINS MB: Interleukin-2 and high-dose dsplatin in patients with metastatic melanoma: a pilot study. J. Clin. Oncol. (1991) 9:1821–1830.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO, OLDHAM RK, BARTH NM, BIRCH R, ARNOLDJ, WEST W: Recombinant interleukin-2 and adoptive immunotherapy alternating with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. J. Natl. Cancer Inst. (1990) 82:1345–1349.
   PubMed Web of Science ®Google Scholar
• FIAHERTY L: The combination of recombinant inter-leultin-2 and dacarbazine (DIX) in metastatic mela-noma. Cancer Treat. Rev. (1989) 16\(Suppl. 1):65–66.
   Google Scholar
• FLAHERTY LE, ROBINSON W, REDMAN BG, GONZALEZ R, MARTINO S, KRAUT M, VALDIVIESO M, RUDOLPH AR: A Phase II study of dacarbazine and cisplatin in combina-tion with outpatient administered interleukin-2 in me-tastatic malignant melanoma. Cancer (1993) 71:3520–3525.
   PubMed Web of Science ®Google Scholar
• ATKINS MB, O'BOYLE KR, SOSMAN JA, WEISS GR, MAR-GOLIN KR, ERNEST ML, KAPPLER K, MIER JW, SPARANO JA, FISHER RI, ECKARDT JR, PEREIRA C, ARONSON FR: Multi-institutional Phase 1:1 trial of intensive combina-tion chernoinununotherapy for metastatic melanoma. J. OM. Oncol. (1994) 12:1553–1560.
   PubMedGoogle Scholar
• KHAYAT D, ANTOINE E, RIKE 0, TOLTRANI JM, YUJI TFM1N E, BOREL Ch, BENHAMMOUDA A, THILL L, FRANKS C, AUGLERG G, WELL M, SOUBRANE Cl, BANZETP: Chemolm-munotherapy of metastatic malignant melanoma. The Salpedere Hospital (SOMPS) experience. Eur. J. Cancer (1993) 29A\(Suppl. 5):S1–55.
   Google Scholar
• RICHARDS JM, MEHTA N, RAMMING K, SKOSEY P: Sequen-tial chemohnmunotherapy in the treatment of metas-tatic melanoma. J. Clin. Oncol. (1992) 10:1338–1343.
   PubMed Web of Science ®Google Scholar
• KEILHOLZ U, SCHEIBENOGEN C, TILGEN W, BERGMANN L, WEIDMANN E, SEITHER E, RICHTER M, BRADO B, MITROU PS, HUNSTEIN W: Interferon-a and interleukin-2 in the treatment of metastatic melanoma. Cancer (1993) 72:607–614.
   PubMed Web of Science ®Google Scholar
• ICHAYAT D, BOREL C, TOURANI JM, BENHAMMOUDA A, ANTOINE E, RDCE 0, VUILLEMIN E, BAZEX PA, THILL L, FRANKS R, AUCLERC G, SOUBRANE C, BANZET P, WEIL M: Sequential chemoimmunotherapy with cis platin, inter-leultin-2, and interferon alpha-2a for metastatic mela-noma. J. Clin. Oncol. (1993) 11:2173–2180.
   PubMedGoogle Scholar
• ATZPODIEN J, LOPEZ HANNINEN E, KIRCHNER H, FRAN- **ZKE A, KORFER A, VOLKENANDT M, DUENSING S,SCHOMBURG A, CHAITCHIK S, POLIWODA H: Chemoim-munotherapy of advanced malignant melanoma: se-quential administration of subcutaneous interleukin-2 and interferon-a after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, car-mustine and tamoxifen. Eur.J. Cancer(1995) 31a:876-881. OS Most promising results in patients with melanoma.
   Google Scholar
• KRUIT HJ, GOEY SH, CALABRESI F, LINDEMANN, A, STA-HEL RA, POLIWODA H, OSTERWALDER B, STOTER G: Final report of a Phase II study of interieukin-2 and inter-feron a in patients with metastatic melanoma. Br. J. Cancer (1995) 71:1319–1321.
   PubMed Web of Science ®Google Scholar
• DUMMER R, GORE ME, HANCOCK RW, GUILLOU P, GROB-BEN HC, BECKER JC, OSKAM R, DIELEMAN JP, BURG G: A multicenter Phase II clinical trial using dacarbazine for continuous infusion interleukin-2 for atetastatic mela-noma. Cancer (1995) 75:1038–1044.
   PubMed Web of Science ®Google Scholar
• HEYS SD, FRANKS CR, EREMIN 0: Interleukin-2 therapy:current role in surgical oncological practice. Br. J. Slug. (1993) 80:155–162.
   Web of Science ®Google Scholar
• THOMPSON JA, LEE DL, LINDGREN CG, BENZ LA, COLLINS C, LEvirr D, FEFER A: Influence of dose and duration of Infusion of interleukin-2 on toxicity and imnumo-modulation. J. Clin. Oncol. (1988) 6:669–678.
   PubMed Web of Science ®Google Scholar
• MITTELMAN A, HUBERMAN M, PUCCIO C, FALLON, B, TESSITORE J, SAVONA S, EYRE T, GAFNEY E, WICK M, SKELOS A, ARNOLD P, AHMED T, GROOPMAN J, ARLIN Z, ZEFFREN J, avvrrr D: A Phase I study of recombinant human interieultin-2 and alpha-interferon-2a in pa-tients with renal cell cancer, and malignant melanoma. Cancer (1990) 66:664–669.
   PubMed Web of Science ®Google Scholar
• ATZPODIEN J, KORFER A, FRANKS CR, POLIWODA H, KIRCHNER H. Home therapy with recombinant inter-leukin-2 and interferon-a2b in advanced human malig-nancies. Lancet (1990) 335:1509–1512.
   Google Scholar
• LOTZE MT, MATORY YL, RAYNOR AA, ETTINGHAUSEN SE,vErro JT, SEIPP CA, ROSENBERG SA: Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer (1986) 58:2764–2772
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, MUUL LM, LEITMAN S, CHANGAE, ETTINGHAUSEN SE, MATORY YL, SKIBBER H, SHILONI E, VE I 10 JT, SEIPP CA, SIMPSON C, REICHART CM: Obser-vations on the systemic administration of autologous lymphokirte-activated killer cells and recombinant in-terleukin-2 to patients with metastatic cancer. New Engl. J. Med. (1985) 313:1485–1492.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO, CHURCH C, OLDHAM RK, WEST WH, SCHWARTZBERG L, BIRCH R: In-patient continuous-in-fusion interleukin-2 in 788 patients with cancer. Cancer (1993) 71:2358–2370.
   PubMedGoogle Scholar
• HAMBLIN TJ, WILLIAMSON PJ, GEORGE DK, OSKAM R, PALMER PA, FRANKS CR: A Phase II study of human r-IL-2 and 5-FU chemotherapy in the treatment of metastatic colorectal carcinoma. Proc. ASCO (1990) 9:433A
   Google Scholar
• EREMIN 0, HEYS SD, PARK KGM, KEENAN RA, BAYLISSAP, SMITH FW, FRANKS CR: Interleukin-2 therapy in patients with hepatic metastases. Eur. J. Sutg. Oncol. (1992) 18:406.
   Google Scholar
• REID I, SHARPE I, MAXWELL W, MCDEVITT J, FRANKS CR,TANNER WA, MONSON JRT: A Phase II trial of recombi-nant interleukin-2 and 5-fluorouracil in patients with metastatic colorectal carcinoma. Eur. J. Stog. Oncol. (1992) 18:591–598.
   PubMedGoogle Scholar
• YANG JC, SHLASKO E, RITCHEY JL, LANDRY JG, WHITEDE, ROSENBERG SA: Combination chemoimmuno-therapy for metastatic colorectal cancer using 5-fluorouraciL leucovorin and interleukin-2. Eur.J. Cancer (1993) 29A:355–359.
   PubMed Web of Science ®Google Scholar
• HEYS SD, EREMIN 0, RUGGERI EM, PEIN F, RAINER H, 00OSKAM R, DEPEUTER R, PALMER PA, FRANKS CR: A PhaseIII trial of recombinant interleukin-2, 5-fluorouradl and leucovorin versus 5-fluorouracil and leucovorin In patients with unresectable or metastatic colorectal can-cer. Eur.J. Cancer (1995) 31A:19-25. First randomised trial of rIL-2/chemotherapy versus chemotherapy.
   Google Scholar
• HAMBLIN TJ, SADULLAH S, WILLIAMSON P, STEVENSON J, OSKAM R, PALMER P, FRANKS CR: A Phase HI study of recombinant interleukin-2 and fluorouracil chemo-therapy in patients with metastatic colorectal cancer. Br. J. Cancer (1993) 68:1186–1189.
   PubMed Web of Science ®Google Scholar
• RUBIN JI, ELWOOD LJ, ROSENBERG SA, LOTZE MT: Immu-nohistochemical correlates of response to recombinant interleukin-based immunotherapy in humans. Cancer Res. (1989) 49:7086–7092.
   PubMed Web of Science ®Google Scholar
• BLAY J-Y, FAVROT MC, NEGRIER S, COMBARET V, CHOUAIB S, MERCATELLO A, KAEMMERLEN P, FRANKS CR, PHILIP T: Correlation between clinical response to in-terleukin-2 therapy and sustained production of tumor necrosis factor. Cancer Res. (1990) 50:2371–2374.
   PubMed Web of Science ®Google Scholar
• BLAY J-Y, NEGRLER S, COMBARET V, ATTALI S, GOILLOTE, MERROUCHE Y, MERCATELLO A, RAVAULT A, TOURANI J-M, MOSKOVTCHENKO J-F, PHILIP T, FAVROT M: Serum levels of interleukin-6 as a prognostic factor in metas-tatic renal cell cardnoma. Cancer Res. (1992) 52:3317–3322.
   PubMedGoogle Scholar
• DEEHAN DJ, HEYS SD, SIMPSON WG, BROOM J, FRANKS CR, EREMIN 0: In vivo cytokine production and recom-binant interleukin-2 imrnunotherapy: an insight into the possible mechanisms underlying clinical re-sponses. Br. J. Cancer (1994) 69:1130-1135. Differential release of cytokines in responding and non-responding patients.
   Google Scholar
• PARK KGM, HEYS SD, MURRAY JB, HAYES PD, ASHBY JA, FRANKS CR, EREMIN 0: Recombinant interleukin-2 (r1L-2) treatment in patients with metastatic colorectal can-cer: effect on natural cytotoxicity. Cancer Immunol. Immunother. (1992) 35:53-58. Failure to achieve maximum natural cytotoxicity in vivo in patients receiving riL–2.
   Google Scholar
• BROOM J, HEYS SD, WHITING PH, PARK KGM, STRACHAN A, ROTHNIE I, FRANKS CR, EREMIN 0: Interleukin-2 therapy in cancer: identification of responders. Br. J. Cancer (1992) 66:1185–1187.
   PubMed Web of Science ®Google Scholar
• SIMPSON WG, HEYS SD, WHITING PH, EREMIN 0, BROOM J: Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer. Clin. Exp. Immunol. (1995) 99:143-147. Relationship of acute phase response to rIL-2 therapy and survival.
   Google Scholar
• VETTER ML, GEWURZ H, HANSEN B, JAMES K, BAUM LL: Effects of C-reactive protein on human lymphocyte responsiveness. J. Immunol. (1983) 130:2121–2126.
   PubMed Web of Science ®Google Scholar
• HAMOUDI W, BAUM LL: C-reactive protein is involved in calcium dependent programming of natural killer cells. Fed. Proc. (1986) 136:2551–2555.
   Google Scholar
• SALO M: Effects of anaesthesia and surgery on the Immune response. Acta Anaesthesiol. Scand. (1992) 36:201–220.
   PubMed Web of Science ®Google Scholar
• UTOH J, YAMAMOTO T, UTSUNOMIYA T, KAMABRA 'IT,GOTO H, MIYAUVHI Y: Effect of surgery on neutrophil functions, superoxide and leukotriene production. Br. J. Stag. (1988) 75:682–685.
   Web of Science ®Google Scholar
• HEYS SD, KHAN AL, EREMIN 0: Immune suppression in surgery. Postgrad. Surg. (1995) 5:62–67.
   Google Scholar
• TRINCHIERI G: Biology of natural killer cells. Adv. Immu-nol. (1989) 47:187–375.
   PubMed Web of Science ®Google Scholar
• KHAN AL, RICHARDSON S, DREW J, LARSEN F, CAMPBELL M, ASHBY J, HEYS SD, AH-SEE AK, EREMIN 0: Polyadenylic-polyuridylic acid (PAPU) enhances the natural cell-mediated cytotoxicity in patients with breast cancer undergoing mastectomy. Surgery. In press.
   Google Scholar
• UCHIDA A, KOLB R, MICKSCHE M: Generation of supres-sor cells for natural killer cell activity in cancer patients after surgery. J. Natl. Cancer Inst. (1982) 68:735–741.
   PubMed Web of Science ®Google Scholar
• NICOLS PH, RAMSDEN CW, WARD U, TREJDOSIEWICZ LK, AMDROSE NS, PRIMROSE JN: Pen-operative modulation of cellular immunity in patients with colorectal cancer. Clin. Exp. Immunol. (1993)94:4–10.
   PubMed Web of Science ®Google Scholar
• SALISBURY AJ, KINNA JA, GRIFFITHS JD, NAUNTON-MOR-GAN C: Circulating cancer cells during excision of carcinoma of the rectum and colon with high ligation of the inferior mesenteric vein. Sutg. Gynecol. Obstet. (1965) 120:1266–1270.
   PubMed Web of Science ®Google Scholar
• DEEHAN DJ, HEYS SD, ASHBY J, EREMIN 0: Interieukin-2 (11–2) augments host cellular immune reactivity in the pen-operative period in patients with malignant dis-ease. Eur. J. Su. Oncol. (1995) 21:16-22. Reversal of immunosuppression by surgery with rIL-2; implications for patients with cancer.
   Google Scholar
• TAKESHITA T, ASA° H, OHTANI K, ISHII N, KUMAKI S, TANAKA N, MUNAKATA H, NAKAMURA M, SUGAMURA K: Cloning of the y chain of the human IL-2 receptor. Science (1992) 257:379–382.
   PubMed Web of Science ®Google Scholar
• VOSS SD, SONDEL PM ROBB RJ: Characterization of the interleukin-2 receptors (11-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 11-2Ry chain with the IL-2144 chain in func-tional intermediate-affinity IL-2R. J. R. Med. (1992) 176:531–541.
   Web of Science ®Google Scholar
• YASAMURA S, LIN W-C, WEIDMANN E, HIEBDA P, WHITESIDE TL: Expression of interleukin-2 receptorson human carcinoma cell lines and tumour growth inhibition by interleukln-2. Int. J. Cancer (1994) 59:225-234. Demonstration of IL-243 on human cancer cells.
   Google Scholar
• HICKS C, COOLEY MA, PENNEY R: Investigation of inter-leukin-2 receptor on human endothelial cells. Growth Factors (1991) 5:201–208.
   PubMedGoogle Scholar
• WEIDMANN E, SACCHI M, PLAISANCE S, HEO DS, YASA-MURA S, LINN W-C, JOHNSON JT, HERBERMAN RB, AZ-ZARONE B, WHITESIDE TL: Receptors for interleukin-2 on human squamous carcinoma cell lines and tumor in situ. Cancer Res. (1992) 52:5963–5970.
   PubMed Web of Science ®Google Scholar
• PLAISANCE S, RUBINSTEIN E, ALILECHE A, SAHRAOUI Y, KRIEF P, AUGERY-BOURGET Y, JASMIN C, SUAREZ H, AZZARONE B: Expression of the interleukin-2 receptor on human fibroblasts and its biological significance. Int. Immunol. (1992) 4:739–746.
   PubMed Web of Science ®Google Scholar
• SANETO RP, ALTMAN A, KNOBLER RL, JOHNSON HM, DEVELLIS Y: Interleukin-2 mediates the inhibition of oligodendrocyte progenitor cell prolifration in vitro. Proc. Natl. Acad. Sci. USA (1986) 83:9221–9225.
   PubMed Web of Science ®Google Scholar
• HEYS SD, KERNOHAN NM, MURRAY JB, WALKER F, ERE-MIN 0: Expression of the intermediate affinity inter- leukin-2 receptor by a human solid tumour cell line: evidence for functional activity. Int. J. Oncol. (1994) 5:931–935.
   PubMed Web of Science ®Google Scholar
• MCMILLAN DN, KERNOHAN NM, FlETT ME, HEYS SD, ••DEEHAN DJ, SEWELL HF, WALKER F, EREMIN 0: Inter- leuldn-2 receptor expression and interleukin-2 localis- ation in human solid tumour cells in situ and in vitro: evidence for a direct role in the regulation of tumour cell proliferation. Int. J. Cancer (1995) 60:766-772. Demonstration of IL-2R in human tumour cells in vivo and differential effects on growth.
   Google Scholar
• COHEN PJ, LOTZE MT, ROBERTS JR, ROSENBERG SA, JAFFE ES: The hnmunopathology of sequential tumour biop-sies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expres-sion. Am. J. Path. (1987) 129:208–214.
   Google Scholar
• VIEWE.G., J, BOCZKOWSKI D, ROBERSON KM, EDWARDS DW, PHILIP M, PHILIP R, RUDOLL T, SMITH C, ROBERTSON C, GILBOA E: Efficient gene transfer with adeno-associ-ated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res. (1995) 55:2366–2372.
   PubMed Web of Science ®Google Scholar
• FEARON ER, PARDOLL DM, ITAYA T, GOLUMBEK P, LEVIT-SKY HI, SIMONS JW, KARASUYAMA H, VOGELSTEIN B, FROST P: Interleukin-2 production by tumor cells by-passes T helper function in the generation of an antitu-mor response. Cell (1990) 60:397–403.
   PubMed Web of Science ®Google Scholar
• BUBENIK J, SIMOVA J, JANDLOVA T: Lmmunotherapy of cancer using local administration of lymphoid cells transformed by1L-2 cDNA and constitutively producing 11-2. Immunol. Leu. (1990) 23:287–292.
   PubMed Web of Science ®Google Scholar
• LEY V, LANGLADE-DEMOYEN P, KOURILSKY P, LARSSON-SCIARD EV: Interleukin-2-dependent activation of tu-mor-specific cytotoxic T-lymphocytes in vivo. Eur J. Immunol. (1991) 21:851–854.
   PubMed Web of Science ®Google Scholar
• GANSBACHER B, ZIER K, DANIELS B, CRONIN K, BANNERU R, GILBOA E: Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. (1990) 122:1217–1224.
   Google Scholar
• PORGADOR A, GANSBACHER B, BANNERJI R, TZEHOVAL E, GILBOA E, FELDMAN M, EISENBACH L: Anti-metastatic vaccination of tumor-bearing mice with 11-2-gene-in-serted tumour cells. Int. J. Cancer (1993) 53:471–477.
   PubMed Web of Science ®Google Scholar
• NAKAMURA T, WAKIMOTO H, ABE J, KANEGAE Y, SAITO seI, AOYAGI M, HEAKAWA K, HAMADA H: Adoptive immu-notherapy with murine tumour-s pecific T-lymphocytes engineered to secrete interleukin-2. Cancer Res. (1994) 54:5757–5760.
   PubMed Web of Science ®Google Scholar
• CONNOR J, BANNERJI R, SAITO S, HESTON W, FAIR W, GILBOA E: Regression of bladder tumors in mice treated with interleukin-2-gene modified tumor cells. J. Exp. Med. (1993) 177:1127–1134.
   PubMed Web of Science ®Google Scholar
• FAN J, BASS HZ, FAHEY JL: Elevated IFN-gamma and decreased11-2 gene expression are associated with IHV infection. Immunol. (1993) 151:5031–5040.
   Web of Science ®Google Scholar
• ROOK AJ, MASUR H, LANE HC, FREDERICK W, KASAHARA T, MACHER AM, DJEU JY, MANISCHEWITZ JF, JACKSON L, FAUCHI AS, QUINNAN GV: Interleukin-2 activates the suppressed natural killer and cytomegalus-specific cy-toxic activities of lymphocytes from patients with the aquired immunodeficiency syndrome. J. Clin. Invest. (1983) 72:398-403.108.
   Google Scholar
• TEPPLER H, KAPLAN G, SMITH ICA, MONTANA AL, MEYN P, COHN ZA: Prolonged immunostimulatory effect of low-dose polyethylene glycol interleulchx-2 in patients with human immunodeficiency virus type 1 infection. J. Exp. Med. (1993) 177:483–492.
   PubMed Web of Science ®Google Scholar
• WOOD R, MONTOYA JG, KUNDU SK, SCHWARTZ DH, MERIGAN TC: Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human im-munodeficiency virus type 1 infection: a Phase I/I1 study. J. Infect. Dis. (1993) 167:519–525.
   PubMed Web of Science ®Google Scholar
• MCMAHON DK, ARMSTRONG JA, HUANG XL, RINALDO CR, GUPTA P, WHITESIDE TL, PAZIN GJ, TRIPOLI C, HO M: A Phase I study of subcutaneous recombinant inter-leukin-2 in patients with advanced disease while on zidovidine. AIDS (1994) 8:59–66.
   PubMed Web of Science ®Google Scholar
• KOVACS JA, BASELER M, DEWAR RJ, VOGEL S, DAVEY RT, FALLOON J, POLIS MA, WALKER RE, STEVENS R, SALZMANNP, METCALF JA, MASUE H, LANE HC: Inceases in CD4 T-Iymphocytes with intermittent courses of inter-leukin-2 in patients with human immunodeficiency virus infection. New Engl. J. Med. (1995) 332:567-575. Enhancement of immune function in patients with HIV infection.
   Google Scholar
• MODLIN RL: Th1-Th2 paradigm insights from leprosy. J. Invest. Dermatol. (1994) 102:828–832.
   PubMed Web of Science ®Google Scholar
• YAMAMURA M, UYEMURA K, DEANS RJ, WEINBERG K, REA TH, BLOOM BR, MODLIN EL: Defining protective re-sponses to pathogens: cytokine profiles in leprosy lesions. Science (1991) 254:277–279.
   PubMed Web of Science ®Google Scholar
• YAMAMURA M, WANG X-H, OHMEN JD, UYEMURA K, REO TH, BLOOM BR, MODLIN EL: Cytokine patterns in immu-nologically mediated tissue damage. J. Immunol. (1992) 149:1470–1475.
   PubMed Web of Science ®Google Scholar
• VAN VOORIS WC, KAPLAN G, SARNO EH, HORWITZ MA, STEINMAN RM, LEVIS WR, NOGUEIRA N, HAIR LS, GATASS CR, ARRICK BA, COHN ZA: The cutaneous infiltrates of leprosy: cellular characteristics and the predominant T-cell phenotypes. New Engl.J. Med. (1982) 307:1593–1597.
   PubMed Web of Science ®Google Scholar
• MODLIN EL, HOFMAN FM, TAYLOR CR, REA TH: T Lym-phocyte subsets in the skin lesions of patients with leprosy. J. Am. Acad. Dermatol. (1983) 8:182–189.
   PubMed Web of Science ®Google Scholar
• KAPLAN G, BRITTON WJ, HANCOCK GE, THEUVENET WJ, SMITH KA, JOB CK, ROCHE PW, MOLLOY A, BUR1CHARDT R, BARKER J, PRADHAN HM, COHEN ZA: The systemic influence of recombinant interleukin-2 on the manifes-tations of lepromatous leprosy. J. Exp. Med. (1991) 173:993–1006.
   PubMed Web of Science ®Google Scholar
• DEWYS WD, BEGG D, LAVIN PT AND THE EASTERN COOPERATIVE ONCOLOGY GROUP: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am. J. Med. (1980) 69:491–497.
   PubMed Web of Science ®Google Scholar
• DIXON DW, HEYMSFOELD SB, COHEN AE, KUTNER ANSLEY J, LAWSON DH, RUDMAN D: Protein-calorie undernutrition in hospitalbrd cancer patients. Am. J. Med. (1980) 68:683–690.
   PubMed Web of Science ®Google Scholar
• MEGUID MM, MUGHAL MM, DEBONIS D, MEGUID V, TERZ JJ: Influence of nutritional status on the resumption of adequate food intake in patients recovering from col-orectal cancer cooperations. Surg. Clin. North Am. (1986) 66:1167–1176.
   PubMed Web of Science ®Google Scholar
• BEUTLER B, CERAMI A: Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature (1986) 320:584–588.
   PubMed Web of Science ®Google Scholar
• FEARON KCH, MCMILLAN DC, PRESTON T, WINSTANLEY FRP, CRULKSHANK AM, SHENKIN A: Elevated circulating interleukin-6 is associated with an acute phase re-sponse but reduced fixed hepatic protein synthesis in patients with cancer. Ann. Surg. (1991) 21:325–331.
   Google Scholar
• GOUGH DB: Educate the phagocyte! Br. J. Surg. (1991) 78:1–2.
   Web of Science ®Google Scholar
• NORTON JA, FRAKER DL: Tolerance to tumor necrosis factor. Nutrition (1989) 5:131–135.
   PubMed Web of Science ®Google Scholar
• MONSON JRT, RAMSDEN C, GUILLOU PJ: Decreased inter-leukin-2 production in patients with gastrointestinal cancer. Br. J. Stag. (1986) 73:483–486.
   Web of Science ®Google Scholar
• LAHDEVIRTA J, MAURY CPJ, TEPPO A, REPO H: Elevated levels of circulating TNF/tumor necrosis factor in pa-tients with acquired Immunodeficiency syndrome. J. Med. (1988) 85:289–291.
   Google Scholar
• RODRICK ML WOOD JJ, O'MAHONEY JB, DAVIS CF, GRBIC JT, DEMLING RH, MOSS NM, SAPOROSCHETZ I, JORDAN A, D'EON P: Mechanisms of immunosuppression asso-ciated with severe nonthermal traumatic injuries in man: production of interleukin-1 and -2. J. Clin. Immu-nol. (1986) 6:310–318.
   PubMed Web of Science ®Google Scholar
• GOUGH DB, FEARON KCH, WINSTANLEY PW, CARTER DC: Control of TNT production in normal humans and in patients with advanced malignancy. Arch. Surg. (1992) 127:713–717.
   PubMedGoogle Scholar
• GOUGH DB: Ph.D. Thesis. National University of Ireland, Merrion Square, Dublin.
   Google Scholar
• GOUGH DB, FEARON KCH, CARTER DC: Metabolic distur-bance and endotoxin sensitivity in patients with ad-vanced cancer. Submitted for publication to Clinical and Experimental Immunology.
   Google Scholar
• GOUGH DB, WINSTANLEY P, TANNER WA, CARTER DC: Reduction of monocyte INF production in vitro and tumor-induced endotoxin sensitivity in vivo with I1-2. Br. J. Surg. (1995) 82:688–689.
   Web of Science ®Google Scholar
• GOUGH DB, MOSS NM, JORDAN A, GRBIC JT, RODRICK M, MANNICK JA: Recombinant 11-2 (r11-2) improves Immune responses and host resistance to septic chal-lenge in thermally injured mice. Surgery (1988)104:293–300.
   Google Scholar
• GOUGH DB, JORDAN A, MANNICK JA, RODRICK ML: Impaired cell mediated immunity in experimental ab-dominal sepsis and the effect of interleukin-2. Arch. Surg. (1992) 127:859–863.
   PubMed Web of Science ®Google Scholar
• GOUGH DB, GRBIC JT, MANNICK JA, RODRICK ML, ERE-MIN 0: The interaction of interleukin-2 and endotoxin on a component of the macrophage endotoxin recep-tor. Br. J. Surg. (1996). In press.
   Google Scholar